The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 8, Pages 1704
Publisher
MDPI AG
Online
2017-08-04
DOI
10.3390/ijms18081704
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program
- (2017) Linong Ji et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases
- (2017) Kyunghee Byun et al. PHARMACOLOGY & THERAPEUTICS
- Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis
- (2017) Gyeongsil Lee et al. PLoS One
- Gender and age effects on risk factor-based prediction of coronary artery calcium in symptomatic patients: A Euro-CCAD study
- (2016) R. Nicoll et al. ATHEROSCLEROSIS
- The role of cytokines in the development of atherosclerosis
- (2016) A. R. Fatkhullina et al. BIOCHEMISTRY-MOSCOW
- Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
- (2016) Christian Sonesson et al. Cardiovascular Diabetology
- Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics
- (2016) A.J. Scheen DIABETES & METABOLISM
- Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
- (2016) Jan H. Cornel et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
- (2016) Ji Hye Han et al. DIABETOLOGIA
- Statin Use for the Primary Prevention of Cardiovascular Disease in Adults
- (2016) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/−Mice
- (2016) Weiling Leng et al. MEDIATORS OF INFLAMMATION
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Repetitive Glucose Spikes Accelerate Atherosclerotic Lesion Formation in C57BL/6 Mice
- (2015) Yuki Shuto et al. PLoS One
- Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
- (2015) Shirong Qiang et al. Diabetology & Metabolic Syndrome
- Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study
- (2014) A. Kashiwagi et al. DIABETES OBESITY & METABOLISM
- A Comprehensive Review on Metabolic Syndrome
- (2014) Jaspinder Kaur Cardiology Research and Practice
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- The Concept of Metabolic Syndrome: Contribution of Visceral Fat Accumulation and Its Molecular Mechanism
- (2011) Yuji Matsuzawa et al. Journal of Atherosclerosis and Thrombosis
- (1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment
- (2010) Hiroyuki Kakinuma et al. JOURNAL OF MEDICINAL CHEMISTRY
- Hyperglycemia-Induced Reactive Oxygen Species Increase Expression of the Receptor for Advanced Glycation End Products (RAGE) and RAGE Ligands
- (2009) D. Yao et al. DIABETES
- Cytokines and atherosclerosis: a comprehensive review of studies in mice
- (2008) R. Kleemann et al. CARDIOVASCULAR RESEARCH
- Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice
- (2008) F. Johansson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started